Cargando…

#2714, a novel active inhibitor with potent G2/M phase arrest and antitumor efficacy in preclinical models

Arresting cell cycle has been one of the most common approaches worldwide in cancer therapy. Specifically, arresting cells in the G2/M phase is a promising therapeutic approach in the battle against lung cancer. In the present study, we demonstrated the anticancer activities and possible mechanism o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Wen-Jie, Peng, Wen, Sun, Qian-Qian, Li, Yong-Huai, Chen, Bo, Yu, Luo-Ting, Xu, You-Zhi, Wang, Si-Ying, Zhao, Ying-Lan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5841443/ https://www.ncbi.nlm.nih.gov/pubmed/29531821 http://dx.doi.org/10.1038/s41420-018-0032-y

Ejemplares similares

Novel agent #2714 potently inhibits lung cancer growth by suppressing cell proliferation and by inducing apoptosis in vitro and in vivo
por: Lu, Wenjie, et al.
Publicado: (2019)

Nurse‐led one stop hematuria clinic: Outcomes from 2,714 patients
por: Madaan, Anika, et al.
Publicado: (2021)

2714. Invasive Fungal Disease in Lung Transplant Recipients: Incidence, Risk Factors, and Outcomes
por: Kovac, Victor, et al.
Publicado: (2023)

A novel VEGFR inhibitor ZLF-095 with potent antitumor activity and low toxicity
por: Li, Xiao, et al.
Publicado: (2023)

2714. Streptococcus pneumoniae Nasopharyngeal Carriage in Canadian Adults Hospitalized with Community-Acquired Pneumonia from 2010 to 2017
por: LeBlanc, Jason J, et al.
Publicado: (2019)

Oxoaporphine Metal Complexes (Co(II), Ni(II), Zn(II)) with High Antitumor Activity by Inducing Mitochondria-Mediated Apoptosis and S-phase Arrest in HepG2
por: Qin, Jiao-Lan, et al.
Publicado: (2017)

Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor
por: Liu, Yahong, et al.
Publicado: (2023)

YLT192, a Novel, Orally Active Bioavailable Inhibitor of VEGFR2 Signaling with Potent Antiangiogenic Activity and Antitumor Efficacy in Preclinical Models
por: Xia, Yong, et al.
Publicado: (2014)

Visual and Refractive Outcomes of Cataract Surgeries Performed in One Year in a Private Practice Setting: Review of 2714 Procedures
por: Rementería-Capelo, Laureano A., et al.
Publicado: (2020)

Oleanolic acid induces mitochondrial-dependent apoptosis and G0/G1 phase arrest in gallbladder cancer cells
por: Li, Huai-Feng, et al.
Publicado: (2015)

Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models
por: Grünewald, Sylvia, et al.
Publicado: (2019)

Correspondence: Some general points regarding Ledberg and Wennberg, BMC Medical Research Methodology 2014 April 27;14:58
por: Böhning, Dankmar, et al.
Publicado: (2015)

Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer
por: Chen, Xiu-Xiu, et al.
Publicado: (2015)

NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models
por: Jensen, Michael Rugaard, et al.
Publicado: (2008)

AMG-510 and cisplatin combination increases antitumor effect in lung adenocarcinoma with mutation of KRAS G12C: a preclinical and translational research
por: Wu, Lei-Lei, et al.
Publicado: (2023)

Erratum to: Correspondence: Some general points regarding Ledberg and Wennberg, BMC Medical Research Methodology 2014 April 27;14:58
por: Böhning, Dankmar, et al.
Publicado: (2015)

Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor
por: Chung, Suyoun, et al.
Publicado: (2016)

CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest
por: Wang, Jiayuan, et al.
Publicado: (2017)

MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models
por: Fang, Douglas D., et al.
Publicado: (2021)

Potent antitumor activity of oncolytic adenovirus expressing Beclin-1 via induction of autophagic cell death in leukemia
por: Tong, Yin, et al.
Publicado: (2013)

Correction: Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor
por: Chung, Suyoun, et al.
Publicado: (2020)

D‐1553: A novel KRAS(G12C) inhibitor with potent and selective cellular and in vivo antitumor activity
por: Shi, Zhe, et al.
Publicado: (2023)

Preclinical anti-arthritic study and pharmacokinetic properties of a potent histone deacetylase inhibitor MPT0G009
por: Hsieh, I-N, et al.
Publicado: (2014)

Inhibitors of Anti-apoptotic Bcl-2 Family Proteins Exhibit Potent and Broad-Spectrum Anti-mammarenavirus Activity via Cell Cycle Arrest at G0/G1 Phase
por: Kim, Yu-Jin, et al.
Publicado: (2021)

Betulinic acid exerts potent antitumor effects on paclitaxel-resistant human lung carcinoma cells (H460) via G2/M phase cell cycle arrest and induction of mitochondrial apoptosis
por: Zhan, Xiao-Kai, et al.
Publicado: (2018)

Study of the antitumor mechanisms of apiole derivatives (AP-02) from Petroselinum crispum through induction of G0/G1 phase cell cycle arrest in human COLO 205 cancer cells
por: Wu, Kuan-Hsun, et al.
Publicado: (2019)

Development of a novel lactate dehydrogenase A inhibitor with potent antitumor activity and immune activation
por: Du, Mengyan, et al.
Publicado: (2022)

Novel G9a/DNMT first-in-class dual reversible inhibitor has potent antitumor effect in bladder cancer
por: Kwon, Whi-An, et al.
Publicado: (2020)

A Novel Time-Dependent CENP-E Inhibitor with Potent Antitumor Activity
por: Ohashi, Akihiro, et al.
Publicado: (2015)

SRF617 Is a Potent Inhibitor of CD39 with Immunomodulatory and Antitumor Properties
por: Warren, Michael C., et al.
Publicado: (2023)

Benzothiazinethione is a potent preclinical candidate for the treatment of drug-resistant tuberculosis
por: Gao, Chao, et al.
Publicado: (2016)

The Topoisomerase 1 Inhibitor Austrobailignan-1 Isolated from Koelreuteria henryi Induces a G2/M-Phase Arrest and Cell Death Independently of p53 in Non-Small Cell Lung Cancer Cells
por: Wu, Chun-Chi, et al.
Publicado: (2015)

A systemically administered detoxified TLR4 agonist displays potent antitumor activity and an acceptable tolerance profile in preclinical models
por: Chettab, Kamel, et al.
Publicado: (2023)

Preclinical evaluation of Amblyomin-X, a Kunitz-type protease inhibitor with antitumor activity
por: Maria, Durvanei A., et al.
Publicado: (2018)

MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway
por: Lee, Jen-Chieh, et al.
Publicado: (2022)

Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines
por: Eustace, Alex J, et al.
Publicado: (2008)

Targeting inhibitors of apoptosis proteins suppresses medulloblastoma cell proliferation via G2/M phase arrest and attenuated neddylation of p21
por: Chen, Shu‐Mei, et al.
Publicado: (2018)

Knockdown of nucleophosmin induces S-phase arrest in HepG2 cells
por: Wang, Qing-Qing, et al.
Publicado: (2011)

Casticin induces apoptosis and G0/G1 cell cycle arrest in gallbladder cancer cells
por: Song, Xiao-ling, et al.
Publicado: (2017)

Preclinical Evaluation of Discorhabdins in Antiangiogenic and Antitumor Models
por: Harris, Emily M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7u895g70rb4j2cp3r693pho1li